← All trials
NCT05487417
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Jun 1, 2025
- Completion date
- Oct 1, 2025
- First posted
- Aug 4, 2022
- Last posted
- Aug 4, 2022
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xijing HospitalLead sponsor
- Jiao Tong UniversityCollaborator
- Xijing HospitalReponsible party - principal investigator
- Xi’an Gaoxin HospitalCollaborator
- Xi'an XD Group HospitalCollaborator
- First People's Hospital of XianyangCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.